The DKK1 Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma line KYSE-30. This product delivers a heterogeneous pool of cells carrying targeted disruption of the DKK1 gene, providing a robust loss-of-function model for investigating Wnt/??-catenin signaling in an epithelial tumor context. The polyclonal format avoids clonal selection artifacts and offers immediate access to a population-level knockout, suitable for functional genomics, drug screening, and pathway analysis.
KYSE-30 cells originate from a well-differentiated esophageal squamous cell carcinoma and retain key epithelial characteristics, making them an established in vitro system for esophageal cancer research. These adherent cells exhibit typical squamous morphology and harbor genetic features relevant to esophageal carcinogenesis. As a defined tumor cell line, KYSE-30 provides a consistent and pathologically relevant background for studying oncogenic signaling networks and testing therapeutic interventions.
DKK1 encodes dickkopf-related protein 1, a secreted antagonist of the canonical Wnt/??-catenin pathway. Mechanistically, DKK1 binds to LRP5 and LRP6 coreceptors and the transmembrane proteins KREMEN1 and KREMEN2, promoting internalization of the Wnt receptor complex and thereby inhibiting signal transduction. Under normal conditions, this interaction prevents ??-catenin stabilization and blocks TCF/LEF-mediated transcription of target genes such as MYC and CCND1. The expression of DKK1 is regulated by upstream factors including TP53, GLI1, and TGF-??, and it functions downstream of multiple signaling inputs. Its activity intersects with key pathway components like Frizzled, DVL, GSK3??, AXIN, APC, and ??-catenin, positioning DKK1 as a critical nodal regulator of cell proliferation, differentiation, and apoptosis.
In KYSE-30 cells, disruption of DKK1 removes its inhibitory constraint on Wnt/??-catenin signaling, leading to elevated ??-catenin levels, enhanced TCF transcriptional activity, and upregulation of pro-proliferative and pro-migratory genes. This knockout model recapitulates a state of aberrant Wnt activation often observed in esophageal squamous cell carcinoma, where epigenetic silencing or downregulation of DKK1 has been associated with tumor progression. The polyclonal DKK1-null KYSE-30 population thus serves as a valuable tool for dissecting the tumor-suppressive role of DKK1 and for evaluating the consequences of unrestrained Wnt pathway activity in a disease-relevant cellular context.
Researchers can employ this polyclonal knockout model in a wide range of experimental workflows. Typical applications include Wnt reporter assays using TOPFlash to quantify TCF/LEF-driven transcription, immunofluorescence microscopy to assess ??-catenin subcellular localization, and Western blotting or RT-qPCR for measuring changes in MYC, CCND1, and ??-catenin expression. Functional assays such as migration, invasion, proliferation, and apoptosis analyses can directly probe phenotypic outcomes of DKK1 loss. Moreover, the cells are ideal for drug sensitivity screening targeting the Wnt pathway and for transcriptomic studies via RNA-seq to map global gene expression changes. For further information or to discuss custom CRISPR services, please contact Ascent Research.
